Overview

Efficacy and Safety of TD-1473 in Crohn's Disease

Status:
Active, not recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

A Phase 2 study to evaluate the efficacy, safety and tolerability of TD-1473 in subjects with moderately-to-severely active Crohn's Disease with up to 48 weeks of treatment.

Phase:

Phase 2

Details

Lead Sponsor:

Theravance Biopharma